Company says it has isolated virus strains for research
Shenzhen Kangtai Biological Products Co has successfully isolated multiple strains of the Delta variant of the coronavirus in a step that could lead to improved vaccines, media reported on Wednesday.
The report by Shenzhen Special Zone Daily quoted a company executive as saying quality requirements for human vaccines will be strictly followed in the evaluation of the isolated strains.
"In response to new challenges in global epidemic prevention and control, Kangtai will fully promote the R&D and industrialization of the vaccine against the coronavirus variant," the executive said, adding that the inactivated COVID-19 vaccine developed by the company and approved for emergency use in China, is still protective and produces a good immune response to a variety of coronavirus variants.
- 10 dead and 84 injured in explosion at steel plant
- China unveils flexible urban planning rules to improve lives, foster new industries
- Ex–China Construction Bank executive gets 18 years for bribery, loan violations
- First batch of eco-friendly pioneer zones for construction of beautiful countryside unveiled
- Woodpeckers, finches captured in Jilin winter scenes
- Mainland reiterates 1992 Consensus as foundation for resuming cross-Strait dialogue































